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Abstract
Aims/hypothesis The majority of infants with neonatal diabe-
tes mellitus present with severe ketoacidosis at a median of
6 weeks. The treatment is very challenging and can result in
severe neurological sequelae or death. The genetic defects that
cause neonatal diabetes are present from birth. We aimed to
assess if neonatal diabetes could be diagnosed earlier by mea-
suring glucose in a dried blood spot collected on day 5 of life.
Methods In this retrospective case–control study we retrieved
blood spot cards from 11 infants with genetically confirmed
neonatal diabetes (median age of diagnosis 6 [range 2–112]
days). For each case we also obtained one (n = 5) or two
(n = 6) control blood spot cards collected on the same day.
Glucose was measured on case and control blood spot cards.
We established a normal range for random glucose at day 5 of
life in 687 non-diabetic neonates.
Results All 11 neonates with diabetes had hyperglycaemia
present on day 5 of life, with blood glucose levels ranging
from 10.2 mmol/l to >30 mmol/l (normal range 3.2–
6.0 mmol/l). In six of these neonates the diagnosis of diabetes
was made after screening at day 5, with the latest diagnosis
made at 16 weeks.
Conclusions/interpretation Neonatal diabetes can be detected
on day 5 of life, preceding conventional diagnosis in most
cases. Earlier diagnosis by systematic screening could lead
to prompt genetic diagnosis and targeted treatment, thereby
avoiding the most severe sequelae of hyperglycaemia in
neonates.
Keywords Blood spots . Glucose . Neonatal diabetes .
Newborn . Screening
Abbreviation
EFSOCH Exeter Family Study of Childhood Health
Introduction
Neonatal diabetes mellitus is a genetic disorder with an inci-
dence of approximately 1 in 90,000 live births [1–3]. From
birth there is severely reduced insulin production either due to
reduced function or number of insulin producing beta cells.
There are 23 known genetic causes that account for >80% of
diabetes diagnoses in neonates <6 months of age [4]. Defining
the genetic diagnosis is important as individuals with one of
the two most common subtypes (KCNJ11 and ABCC8) can
achieve excellent glucose control with oral sulfonylurea tab-
lets, avoiding a lifetime of insulin treatment and reducing the
need for blood glucose monitoring [5–8].
At present, infants with neonatal diabetes are often
unrecognised as being seriously ill until hyperglycaemia
reaches life threatening levels. Typically, individuals present
in the first 6 months (median age 6 weeks) with severe
ketoacidosis associated with vomiting, dehydration, glucose
>50 mmol/l and acidosis [8]. The treatment of paediatric dia-
betic ketoacidosis is extremely challenging; many babies die
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and those that do not may be left with life changing brain
damage that requires lifelong institutional care [9–11]. These
morbidity and mortality rates are likely to be a marked under-
estimate as brain damage and death from ketoacidosis in
babies is often unrecognised or unrecorded [12].
The genetic defect causing neonatal diabetes is present
within the developing pancreas in utero, leading to reduced
insulin secretion from the fetal pancreas. Reduced insulin se-
cretion may result in reduced insulin-mediated growth and
hence a markedly lower than average birthweight in these
individuals (2600 g compared with 3500 g in those unaffect-
ed) [13]. Insulin deficiency from birth will result in a high
blood glucose level that could be detected in the first few days
of life.
All newborns in the UK are offered a heel prick test where a
small amount of blood is collected onto paper filter cards to
test for nine rare but serious metabolic diseases [14]. The
incidence of the conditions screened for range from 1:2000
to 1:300,000 live births [15]. Newborn screening presents a
clear opportunity for systematic testing for the raised glucose
seen in neonatal diabetes. Dried blood spots in the UK are
collected from newborns at day 5–7 of life and sent to special-
ist screening laboratories by post. Upon receipt they are typi-
cally analysed the same day, as such a putative screening test
would require the analyte to be stable at room temperature for
at least 48 h.
The aim of this study is to establish the stability of blood
spot glucose and to assess the diagnostic accuracy of blood
spot glucose collected at day 5 of life for detecting neonatal
diabetes.
Methods
Participants
Glucose stability study Twenty volunteers were recruited
for the glucose stability study as part of the Exeter 10,000
Project undertaken at the Exeter NIHR Clinical Research
Facility (Exeter, UK). Volunteers were identified by re-
search nurses and residual blood samples were used to
make blood spots.
The study was approved by the Frenchay South West
National Research Ethics Service Committee, UK (REC 09/
H0106/75). Written informed consent was obtained from all
participants.
Establishing a glucose normal range for neonates at day 5
of life Families were recruited as part of the Exeter Family
Study of Childhood Health (EFSOCH), a 5 year prospective
study started in 1999, with the aim of examining genetic in-
fluences on fetal and early growth [16]. As part of this study
all newborns (n = 687) had heel prick capillary blood
measured at day 5 of life at the same time that a dried blood
spot card was collected.
Recruitment of infants with neonatal diabetes From a co-
hort of 170 infants in the UK with genetically confirmed
neonatal diabetes we contacted the referring clinicians of
42 of the most recently diagnosed (diagnosed between
2009 and 2015) to request permission to retrieve the dried
blood spot cards for blood spot glucose analysis. If per-
mission was received, the relevant screening laboratory
was contacted and one of the participant’s original dried
blood spots, and also one/two anonymous control blood
spots from infants who had their dried blood spot cards
collected on the same day, were sent to Exeter for glucose
analysis.
Materials
Analyses were undertaken in the Blood Sciences Research
Laboratory of Royal Devon and Exeter Hospital (Exeter,
UK) or the Derriford Combined Laboratories (Plymouth,
UK).
Blood spot elution Blood spot eluent was prepared by
punching a 3 mm blood spot from each participant’s dried
blood spot card, to which 125 μl of a 2% trichloroacetic acid
solution (Sigma-Aldrich, Dorset, UK) was added and left at
room temperature for 45 min. Samples were subsequently
centrifuged at 1500 g for 1 min and the supernatant fraction
was transferred for glucose analysis.
Glucose analysis Blood spot eluent glucose levels were mea-
sured using a manual rate-reaction hexokinase method
(Randox, Belfast, UK) on a PerkinElmer Lambda 20 UV/
VIS Spectrometer (PerkinElmer, London, UK). Measured el-
uent glucose levels were related back to capillary glucose
levels using a one point calibration (calibration blood spot
prepared using a 50% hematocrit-adjusted glucose calibration
material [Randox]). The total intra-assay CV for blood spot
glucose (including extraction) is 10.3% at 3 mmol/l and 15%
at 14 mmol/l.
Methods
Establishing the stability of glucose on dried blood
spots From each participant (n = 20) we generated 16 blood
spots (approximately 1.5 ml of blood) using standard dried
blood spot cards. At the time of collection the first blood spot
was allowed to dry for 2 h and then eluted and analysed for
baseline glucose. The remaining 15 blood spots from each
participant were split into three groups, with one-third
(n = 5) stored at room temperature, one-third (n = 5) in the
fridge (4°C) and one-third (n = 5) in the freezer (−20°C). One
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blood spot from each temperature condition was then analysed
for glucose at 1, 2, 3, 7 and 14 days post initial collection to
establish a stability profile.
Establishing a glucose normal range for neonates at day 5
of life As part of the EFSOCH study [16] each newborn
(n = 687) had heel prick capillary blood glucose measured
on the Bayer Elite glucose meter (Bayer, Newbury, UK) at
day 5 of life [17].
Dried blood spot glucose levels in infants with neonatal
diabetes Dried blood spots from UK infants with neona-
tal diabetes and paired control samples had been stored
for variable lengths of time (see Table 1) and under var-
iable conditions (ambient temperature and refrigerated)
leading to variable glucose degradation. To allow for this
variable degradation, we adjusted blood spot glucose for
each participant to account for the fall in the glucose
values seen in the simultaneous control samples.
Therefore, for each participant an adjustment factor was
calculated using data from the simultaneous control
samples:
(1) Adjustment factor = mean glucose of reference range
(4.6 mmol/l) / mean glucose of all simultaneous control
samples
(2) Adjusted glucose = measured blood spot glucose ×
adjustment factor.
This analysis made the following assumptions: (1)
degradation of blood spot glucose was proportional in
case and control samples, (2) control blood spot glucose
reflected the mean glucose of the normal range for neo-
nates at day 5 of life.
Statistical analyses
For the stability study, glucose results are presented as mean
percentage change from baseline with 95% CI. Percentage
changes of glucose >10% from baseline concentrations were
considered clinically significant. Differences between the
baseline and the level of glucose at 14 days were assessed
by the Wilcoxon test.
A normal range was established for newborns at day 5 of
life by calculating the mean and the range incorporated by
1.96 SD each side of the mean. Comparison of glucose level
on blood spots from infants with and without neonatal diabe-
tes is presented asmedians and range, and differences between
these two groups were assessed using Mann–Whitney U test.
Results
Two week stability experiment
The stability of blood spot glucose under three storage condi-
tions (room temperature, fridge [−4°C] and freezer [−20°C])
over 14 days is shown in Fig. 1. Under all conditions samples
were stable for over 3 days. When stored in the fridge or
freezer there was no significant degradation over 14 days
(98% of baseline CI 84, 112 and 101% of baseline CI 88,
115, respectively). At room temperature samples had degrad-
ed to 84% (p = 0.05) at 7 days and 81% (p = 0.001) at 14 days.
Capillary blood glucose normal range for neonates at day
5 of life
The mean glucose measured in 687 neonates at day 5 of life
was 4.6 mmol/l with an SD of 0.7 mmol/l. This gives a normal
Table 1 Demographics of infants with neonatal diabetes assessed for dried blood spot glucose at day 5
Gene Sex Current
age
(years)
Status Age at
diagnosis
(days)
Birthweight
(g)
Gestation
(weeks)
Projected blood
spot glucose
(mmol/l)
6q24 Female 3 TNDM 2 1353 36 23.3
6q24 Female 2 TNDM 2 2095 36 12.6
6q24 Male 1 TNDM 12 1660 35 28.6
6q24 Male 3 TNDM 21 1990 40 >30
ABCC8 Male 7 TNDM 56 2500 40 27.4
GATA6 Female 3 PNDM 6 1200 37 12.6
GCK Female 5 PNDM 112 2080 42 18.7
GCK Female 2 PNDM 2 1680 38 17.1
GLIS3 Female 5 PNDM 1 1170 35 10.2
GLIS3 Female 1 PNDM 2 1860 39 10.6
KCNJ11 Female 5 PNDM 56 2270 41 >30
PNDM, permanent neonatal diabetes mellitus; TNDM, transient neonatal diabetes mellitus
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range calculated by the mean ± 1.96 SD of 3.2–6.0 mmol/l.
The highest glucose measured in the group was 7.0 mmol/l.
Blood spot glucose levels in infants with neonatal diabetes
Dried blood spots from 11 infants with confirmed monogenic
neonatal diabetes were received (see Table 1 for participant
characteristics). All 11 participants had intra-uterine growth
retardation and birthweights below the second centile for ges-
tation and sex. Age at diagnosis ranged from 2 days to
112 days after birth.
Participants with six different genetic aetiologies were
assessed, including two with a KCNJ11 or ABCC8 mutation,
which account for >40% of all reported neonatal diabetes
diagnoses.
With each neonatal diabetes blood spot we received one
(n = 5) or two (n = 6) control Guthrie blood spot samples
collected on the same day. All neonatal diabetes case samples
had higher glucose than the matched control samples at day 5
of life (see Fig. 2). The median projected glucose of the paired
control samples was 4.6 mmol/l (2.3–6.2 mmol/l) compared
with 18.7 mmol/l (10.2– >30.0 mmol/l) for the neonatal dia-
betes case samples (p < 0.001). All the infants with neonatal
diabetes had glucose levels that were above the normal range
of 3.2–6.0 mmol/l, with the lowest being 6 SD above the mean
of the normal range (10.2 mmol/l). The difference between the
highest blood spot glucose level of all 687 control samples
used in the normal range and the lowest glucose level for an
infant with neonatal diabetes was 3.2 mmol/l or 4.6 SD. There
was no association between glucose level and age of diagnosis
for the infants with neonatal diabetes (p = 0.47).
Discussion
We have shown that blood glucose in infants with a genetic
diagnosis of neonatal diabetes is raised at day 5 of life and can
be detected using blood spot glucose collected as part of the
UK newborn screening programme.
In total we assessed the newborn screening dried blood
spots from 11 infants with neonatal diabetes. All had signifi-
cantly raised blood glucose at day 5 of life and in six partic-
ipants this preceded the clinical diagnosis by up to 16 weeks.
A study of 1030 infants with neonatal diabetes showed that
the mean age of diagnosis for neonatal diabetes is 6 weeks. Of
these infants, 79% were diagnosed after day 5 of life [4]. This
suggests that newborn screening will be able to identify neo-
natal diabetes in the majority of infants before they develop
overt diabetes. Early diagnosis of hyperglycaemia would al-
low rapid genetic testing and early implementation of treat-
ment, potentially avoiding the severe morbidity and mortality
rates associated with the late presentation of diabetes.
A screening strategy requires the test analyte to be stable
for 48 h. Dried blood spots in the UK are collected from
newborns at day 5–7 of life and sent to specialist screening
laboratories using the postal service. Upon receipt blood spots
are typically analysed the same day with abnormal results
called through to healthcare teams immediately. As such a
putative screening test would require the analyte to be stable
at room temperature for at least 48 h.We found that blood spot
glucose is stable in all conditions for 3 days. At room temper-
ature there is a 16% degradation after 7 days. The 3 day sta-
bility of blood spot glucose makes it a feasible test that could
practically be measured within the time restrictions of the
current UK newborn screening programme.
Screening for the early hyperglycaemia in neonatal diabe-
tes could theoretically be achieved with a point of care testing
(POCT) blood glucose or even a local laboratory glucose. This
has the benefit of reducing the time it takes to send the sample
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Fig. 2 Graph showing projected glucose (adjusted for degradation with
time) in Guthrie blood spots collected at day 5 of life for participants with
neonatal diabetes and paired control samples collected on the same day
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Fig. 1 Stability of blood spot glucose stored at room temperature (dotted
black line/squares), in a fridge (4°C, solid black line/triangles) and in a
freezer (−20°C, dashed line/circles) over 14 days. Blood taken from 20
volunteers. Data presented as mean percentage of baseline at each time
point, with error bars representing the 95% CI
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to the screening laboratory and receiving the abnormal result.
However, in practice this would be expensive to implement
and very difficult to monitor and ensure all babies have been
tested systematically with the appropriate follow-up clinical
care pathway for abnormal results. The benefit of adding glu-
cose to the additional newborn screening test repertoire is that
all the infrastructure for sample collection, quality control and
clinical reporting are in place and robustly monitored.
This study provides preliminary data that suggests it
may be possible to systematically screen for neonatal
diabetes. We found that all infants with neonatal diabe-
tes in our cohort had blood spot glucose >3 SD above
the highest glucose in the control cohort. This suggests
that systematic blood spot glucose screening would
have a high diagnostic accuracy for identifying infants
with undiagnosed neonatal diabetes. A screening strate-
gy would also ensure systematic genetic testing, either
on the dried blood spot or a repeat blood sample, to
ensure the correct genetic aetiology is established and,
consequently, the most effective treatment is imple-
mented, such as sulfonylurea therapy in individuals
with ABCC8 or KCNJ11 mutations which can also have
neurological as well as glycaemic therapeutic effect.
Therefore, systematic screening could result in not only
reduced mortality and morbidity rates but also consid-
erable savings through avoiding lifetime disability and
premature death.
When considering the implementation of a new screening
test, it is not enough to diagnose the condition alone. There is a
requirement to show that making the diagnosis will prevent
avoidable complications and death in an acceptable and cost-
effective manner. For a specific test to be considered viable for
a screening programme, a number of criteria have been sug-
gested. The most widely used are those proposed by Wilson–
Jungner, which are designed to appraise the validity of a
screening programme [18] and have been adapted for appli-
cation to screening in the UK [19]. The original criteria are:
(1) the condition being screened for should be an important
health problem;
(2) the natural history of the condition should be well
understood;
(3) there should be a detectable early stage;
(4) treatment at an early stage should be of more benefit than
at a later stage;
(5) a suitable test should be devised for the early stage;
(6) the test should be acceptable;
(7) intervals for repeating the test should be determined;
(8) adequate health service provision should be made for the
extra clinical workload resulting from screening;
(9) the risks, both physical and psychological, should be less
than the benefits;
(10) the costs should be balanced against the benefits.
Screening for neonatal diabetes clearly fulfils criteria
1–4, with compelling evidence that early identification
of neonatal diabetes would avoid many of the severe
complications and deaths associated with unrecognised
early presentation of diabetes. The results of this work
provide preliminary evidence that a suitable, acceptable
and low-risk test exists that can identify neonatal diabe-
tes in a newborn screening programme.
This study has limitations. We assessed the blood spot glu-
cose in a relatively small number of infants with neonatal
diabetes. To confirm the diagnostic accuracy of a screening
strategy, a larger numbers of samples will need to be assessed.
Ideally this will occur close to diagnosis to reduce the degra-
dation seen in storage. The tests were performed retrospective-
ly and the glucose adjusted to the mean control values were
the mean of a population of 5-day-old infants, this required us
to make a number of assumptions on the linear degradation of
blood spot glucose and themean blood spot glucose in the pair
control samples.
A large prospective assessment of the screening strat-
egy will be required to confirm that blood spot glucose
is a viable screening strategy for neonatal diabetes and
this will need to be accompanied by a health economic
analysis to show cost-effectiveness and take into ac-
count that some infants with neonatal diabetes are diag-
nosed before day 5 of life [20]. In addition, not all the
newborn screening programmes around the world are
collected on day 5, with some collected as early as
day 2–3, as such this needs to be modelled into the
screening performance when undertaking a prospective
study and economic evaluation. Finally, the normal
range for blood glucose in the 687 infants at day 5
were analysed on capillary blood and whilst this dem-
onstrates tight glycaemic control in this age group, this
is a different methodology from dried blood spot glu-
cose and therefore direct comparisons may not be ap-
propriate and a normal range on dried blood spot needs
to be derived.
In conclusion, neonatal diabetes can be detected on
day 5 of life by glucose testing on dried blood spot
cards. This is preliminary evidence to support further
consideration of newborn screening. If glucose testing
was performed routinely at 5 days, it could result in
infants being diagnosed before they present with symp-
toms from diabetic ketoacidosis and hence avoid the
permanent and long-term neurological sequelae.
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